Inovio Pharmaceuticals (INO) Q4 2024 earnings summary

Executive summary

• Advanced INO-3107 for recurrent respiratory papillomatosis, resolving CELLECTRA device manufacturing issues and preparing for BLA submission in 2025, with strong clinical durability and efficacy data.

• Strategic priorities include commercial launch readiness, leveraging the DNA medicines platform, and progressing the pipeline, including INO-3112, INO-5401, and INO-4201.

• Announced promising interim results for DNA-encoded monoclonal antibody (DMAb) technology, showing durable in vivo antibody production and no anti-drug antibodies.

• Progressed commercial readiness, including go-to-market strategy, pricing, and organizational build-out for INO-3107.

• Published full Phase 1/2 clinical and immunology data for INO-3107, supporting its mechanism and efficacy.

Financial highlights

• Raised over $72 million in gross proceeds from equity offerings and ATM sales in 2024.

• Operating expenses decreased to $20.5 million in Q4 2024; full-year expenses down 22% to $112.6 million.

• Net loss for 2024 was $107.3 million ($3.95/share), improved from $135.1 million ($6.09/share) in 2023.

• Ended 2024 with $94.1 million in cash, cash equivalents, and short-term investments; cash runway projected into Q1 2026.

• Total revenues were $218,000 for 2024, compared to $832,000 in 2023.

Outlook and guidance

• BLA rolling submission for INO-3107 planned to begin mid-2025, with completion and FDA acceptance targeted by year-end.

• Confirmatory Phase III trial for INO-3107 to be initiated before BLA submission; most sites identified and IRB approvals in place.

• Commercial launch preparations underway, including distribution strategy, pricing, and field force planning.

• Cash runway expected to support operations into Q1 2026, excluding further capital raises.

• Operational net cash burn estimated at ~$27 million for Q1 2025.